focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEkf Diagnostics Regulatory News (EKF)

Share Price Information for Ekf Diagnostics (EKF)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 33.00
Bid: 32.40
Ask: 32.90
Change: 0.00 (0.00%)
Spread: 0.50 (1.543%)
Open: 32.60
High: 33.50
Low: 32.20
Prev. Close: 33.00
EKF Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

22 Apr 2021 07:00

RNS Number : 2293W
EKF Diagnostics Holdings PLC
22 April 2021
 

 

EKF Diagnostics Holdings plc

("EKF", the "Company" or the "Group")

 

Sale of shares by a Director

 

The Board of EKF Diagnostics Holdings plc (AIM: EKF) has been informed that on 20 April 2021 Christopher Mills, Chairman, sold a total of 3,963,591 ordinary shares of 1 pence each in the Company ("Ordinary Shares") at an average price of 80 pence per Ordinary Share.

 

Following this transaction, Christopher Mills' total direct and indirect interest in the Group is 132,150,000 Ordinary Shares representing approximately 29.04% of the Group's total issued share capital.

 

The Notification of Dealing Form required in accordance with UK MAR is set out below.

 

 

 

EKF Diagnostics Holdings plc

www.ekfdiagnostics.com

Christopher Mills, Non-executive Chairman

Tel: +44 (0) 29 2071 0570

Julian Baines, CEO

Richard Evans, FD & COO

N+1 Singer

Tel: 020 7496 3000

Aubrey Powell / George Tzimas (Corporate Finance)Tom Salvesen (Corporate Broking)

Walbrook PR Limited

Tel: +44 (0) 20 7933 8780 or ekf@walbrookpr.com

Paul McManus / Lianne Cawthorne

Mob: +44 (0) 7980 541 893 / +44 (0) 7584 391 303

 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analysers in regular use across more than 100 countries. EKF specialises in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analysers.EKF specialises in the development, production and worldwide distribution of point-of-care analyzers and clinical chemistry reagents for use in hospital and research laboratories, doctor's offices, blood banks and for in-field anaemia screening programmes. EKF is also a bulk manufacturer of enzymes and has custom manufacturing facilities in the USA for a variety of life science products.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Christopher Mills

 

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Non-Executive Chairman

b)

 

Initial notification /Amendment

 

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

EKF Diagnostics Holdings plc

b)

 

LEI

 

 

213800DXTF3EAUK1AR05

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Ordinary shares of £0.01 each

Identification code

GB0031509804

 

b)

 

Nature of the transaction

 

 

Sale of shares

c)

 

Price(s) and volume(s)

Price(s)

Volume(s)

0.80

3,963,591

d)

 

Aggregated information

- Aggregated volume

N/A - Single Transaction

- Price

e)

 

Date of the transaction

 

 

20 April 2021

f)

 

Place of the transaction

 

 

London Stock Exchange

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBRGDSXXDDGBB
Date   Source Headline
21st May 20144:40 pmRNSSecond Price Monitoring Extn
21st May 20144:35 pmRNSPrice Monitoring Extension
20th May 20144:36 pmRNSResult of AGM
20th May 20147:01 amRNSAGM Statement
20th May 20147:00 amRNSSelah to provide Women's Health testing services
19th May 20143:13 pmRNSHolding(s) in Company - Replacement
16th May 20144:35 pmRNSHolding(s) in Company
15th May 20147:00 amRNSDirector/PDMR Shareholding
8th May 20141:10 pmRNSDirector/PDMR Shareholding
7th May 20147:00 amRNSSelah update
30th Apr 20147:01 amRNSHolding(s) in Company
23rd Apr 20144:46 pmRNSHolding(s) in Company
23rd Apr 20143:33 pmRNSHolding(s) in Company
17th Apr 20141:13 pmRNSDirector/PDMR Shareholding
15th Apr 20147:00 amRNSInvestor Teach-In
11th Apr 201411:33 amRNSResults of General Meeting and Total Voting Rights
10th Apr 20149:33 amRNSResult of Offer
31st Mar 20144:46 pmRNSDirector Resignation
31st Mar 201410:01 amRNSHolding(s) in Company
26th Mar 20144:18 pmRNSHolding(s) in Company
24th Mar 20147:00 amRNSHolding(s) in Company Replacement
20th Mar 201411:26 amRNSResult of the Placing
20th Mar 20147:00 amRNSProposed Acquisitions, Placing & Offer
12th Mar 20147:00 amRNSAcquisition of Separation Technology, Inc.
4th Mar 201411:16 amRNSTransfer of production
26th Feb 20147:00 amRNSFinal Results
18th Feb 20147:00 amRNSQuo-Lab registration in Mexico
17th Feb 20147:00 amRNSNotice of Results
28th Jan 201412:21 pmRNSAdditional Listing
27th Jan 20147:00 amRNSYear end trading update
24th Jan 20147:00 amRNSHolding(s) in Company
20th Jan 20147:00 amRNSPointMan enriches low-level mutations from blood
19th Nov 20137:00 amRNSAcute Kidney Injury marker development
4th Nov 20137:00 amRNSNew PointManT DNA enrichment products launched
30th Oct 20133:10 pmRNSHolding(s) in Company
8th Oct 20138:25 amRNSHolding(s) in Company
3rd Oct 20139:03 amRNSChange of Registered Office
25th Sep 201311:34 amRNSHolding(s) in Company
19th Sep 20137:28 amRNSInvestor Results Briefing
16th Sep 20137:00 amRNSInterim Results
14th Aug 20137:00 amRNSInvestor Teach-In
1st Aug 20137:00 amRNSTrading update
25th Jul 20137:00 amRNSInvestor Teach-In
23rd Jul 20137:00 amRNSSenior management update
4th Jul 201312:09 pmRNSHolding(s) in Company
26th Jun 20135:43 pmRNSAnalyst & Investor Teach-In
18th Jun 201310:17 amRNSDirector Share Transfer
11th Jun 20133:52 pmRNSAmendment to Long-Term Incentive Plan
15th May 20134:34 pmRNSResult of AGM
15th May 20137:00 amRNSAGM Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.